CyberKnife radiosurgery is one such SRS modality that can successfully administer high-dose radiation to within 1-mm accuracy for mobile spine targets. 1, 6, 7, 21 Its incorporation of a frameless technique, real-time imaging, and adaptive beam pointing during treatment has offered an alternative to more invasive immobilization techniques while maintaining high-accuracy targeting in the spine.
Despite these technical advances, very little has been described regarding the success of SRS for vertebral hemangioma. Only one study by Sohn et al. has detailed the use of radiosurgery for the treatment of a spinal hemangioma presenting with worsening radiculomyelopathy following a decompression and partial resection of the lesion that was limited by intraoperative bleeding. 25 Additional reporting on SVHs that have been treated using radiosurgery has largely been amalgamated with other or benign pathologies. 12, 18, 25 Thus, we present a detailed account of the first series of SVH treated by hypofractionated radiosurgery.
Methods

Patients
Patients treated for SVH at Stanford Health Care between 2004 and 2011 were identified, and patient characteristics including age, sex, comorbidities, site of lesion, clinical presentation, clinical outcome, radiographic outcome, length of follow-up, and treatment planning values were collected. Treated lesions included 5 thoracic, 1 cervical, and 1 lumbar lesion. Findings are listed in Table 1 . Clinical and radiographic follow-up were requested at 3 and 6 months and every year after the date of surgery.
radiosurgery treatment Planning
The tumor volume ranged from 0.6 to 70.9 cm 3 , the prescription dose from 15 to 27.5 Gy, the prescription isodose from 72% to 83%, and the maximum dose from 18.1 to 36.7 Gy. Lesions were treated in fractions ranging from 1 to 5 sessions (median 1 session). The biologically effective dose (BED) was calculated using the formula nd(1 + d/a/b). The 2-Gy biologically equivalent dose, normalized BED (nBED) was calculated by dividing the BED by (1 + d/a/b) where d is 2 Gy. The a/b for hemangioma was conservatively estimated to be 4.0 Gy. Treatment variables are provided in Table 2 .
radiosurgery Preparation
Prior to treatment, patients with cervical lesions underwent fabrication of an Aquaplast facemask for immobilization (WFR/Aquaplast Corp.). For thoracic as well as lumbar lesions, the patients rested in an Alpha Cradle (Smithers Medical Products). Some cases involving thoracic and lumbar vertebral lesions also required implantation of percutaneous fiducial markers in the posterior bony elements to provide additional radiographic landmarks and aid with movement compensation as previously described. 21 Patient imaging was performed using high-resolution thin-slice CT with a GE Light Speed 8i or 16i scanner (General Electric Medical Systems) after administration of Omnipaque intravenous contrast (iohexol, 350 mg iodine/ml; Nycomed, Inc., GE Healthcare). Subsequent stereotactic MRI studies were obtained and fused to the stereotactic CT scan to improve target identification.
The team of physicians, comprising a neurosurgeon, a radiation oncologist, and a radiation physicist, performed tumor delineation, dose selection, and planning. Informed consent for treatment was obtained from all patients, and IRB approval was granted. The tumor volume was outlined, and inverse treatment planning was performed to achieve a highly conformal treatment plan with efforts to minimize dosing to the spinal cord.
results
Case reports
Case 1
A 72-year-old man presented with right-hand weakness and arm pain 1 week after shoulder surgery in May 2011 to repair what was thought to be a torn rotator cuff derived from a fall 6 months earlier. He had been diagnosed with chronic regional pain syndrome and had been managed with opiates. CT and MRI from additional workup identified cord compression at the T1-2 level due to a vertebral hemangioma (Fig. 1) . The patient underwent decompression and fusion in October 2011, followed by adjuvant SRS for the residual lesion for ongoing pain. Durable pain improvement was noted by 1 year, and by 2 years, the patient no longer required opiates.
Case 2
A 30-year-old woman had acutely severe, worsening midthoracic radicular pain in January 2004. There was also T8-9 dermatomal patchy numbness. The patient had history of a snowboarding accident with injury to her left shoulder 1 year earlier, breast augmentation, a motor vehicle accident, and migraines. Initial MRI identified a midline sagittal T-9 lesion with no appreciable mass effect; thus, it was first suggested that she proceed with conservative observation. The lesion was considered too posterior for safe vertebroplasty. At 13 months of follow-up her pain had worsened, and she opted for SRS. At 6 months, given a lack of response, SRS was repeated. At the next 6-month follow-up, there was a reported 30% reduction in pain as the patient continued to work with the pain management team. Subsequent care included frequent minor procedures as well as vertebroplasty at an outside hospital without additional benefit.
Case 3
A 46-year-old woman had initially presented to an outside facility for embolization of a large S1-3 hemangioma in 1995. There was persistent back pain and decreased right foot sensation in 2002. Workup at this time identified an additional L-2 lesion involving the sacrum, as well as additional clavicular and thoracic lesions. The patient underwent initial embolization. Recurrent back pain brought her to our institution in 2004, where CT imaging confirmed a persistent L-2 lesion involving the sacrum. She underwent repeat embolization with adjuvant SRS. A second round of SRS was performed for her thoracic hemangiomas. She underwent radiological follow-up and was found to have regression of her hemangiomas with no further interventions required.
Case 4
A 60-year-old woman with a history of congenital lymphangioma requiring multiple subcutaneous resections and with baseline left upper-extremity atrophy presented with electromyography-confirmed C-7 radiculopathy in May 2007. MRI identified neuroforaminal involvement of an epidural C5-6 hemangioma, and she subsequently underwent decompression and fusion. There was initial improvement before new medial hand numbness and increased pincer grasp weakness was reported in the month following surgery. She subsequently underwent SRS. At 1-year follow-up there was improved fine motor coordination and stable numbness.
Case 5
A 50-year-old man presented with 2 years of primarily mid-back pain with thoracic radiation. A hemangioma localized to the T-7 vertebral body, without associated central canal or foraminal stenosis, was discovered during workup (stable spine according to the Spinal Instability Neoplastic Score criteria). Prior to our encounter, he had undergone several epidural injections and radiofrequency ablations, none of which were of benefit. The patient underwent SRS, which did not improve the patient's pain. He continued to work with the pain management team, adjusting medications and undergoing minor procedures.
Clinical results
Patients treated for SVH presented with a wide range of symptoms, with 4 of 5 patients identifying some degree of pain refractory to conservative measures including significant opiate usage and pain clinic interventions. Three patients had dysesthesias, and 2 exhibited upper-extremity weakness.
Following radiosurgery, 4 of 5 patients exhibited some degree of symptomatic improvement: 3 for pain and 1 for weakness. Among the 4 patients who presented with pain, 2 patients (Cases 2 and 5) pursued ongoing outpatient management with minor procedures, including injections, nerve block, spinal cord stimulation trials, and face injections. The patients in Cases 1 and 4 did not require opiates at last follow-up. The time to clinical response for these individuals occurred over an average period of 1 year. One of these patients (Case 4) did not present with primary concerns of pain, but this patient also experienced improvement in strength within 1 year of follow-up.
radiographic results
Prior to SRS, 3 patients demonstrated cord compression, and 1 additional patient presented with neuroforaminal involvement, all with clinical findings consistent with the dermatomal or myotomal distribution of their SVHs. During follow-up, 4 of 5 patients were radiographically monitored. On postoperative MR images, 2 patients (Cases 1 and 3) exhibited shrinking of their tumor's paraspinal component compared with preradiosurgical scans at 6 months, with 20%-40% reduction in the size within a given dimension. One patient did not receive follow-up imaging due to significant improvement in the motor examination results following treatment.
treatment Considerations
All patients were considered for alternative interventions prior to CyberKnife surgery, and 4 of 5 patients underwent a combination of surgical procedures. Two patients (Cases 1 and 4) underwent an initial decompression resection, one with partial resection and the other without. These patients underwent open resection because of their localizable compression and symptoms. Two patients (Cases 3 and 5) considered alternatives prior to SRS, including repeat embolization and vertebroplasty Following primary radiosurgery with partial response, 1 patient (Case 2) ultimately sought vertebroplasty at an outside institution without additional benefit. During follow-up, the patient in Case 4 underwent multiple CyberKnife treatments for her thoracic hemangiomas, given her positive and safe response to treatment to her lumbar lesion. All treatments were well tolerated without subsequent symptoms associated with radiotherapy to the spinal cord.
Discussion
Radiosurgery is rarely considered a primary treatment strategy for SVH, although this may be in part because of the limited evidence currently available. 11 From our cohort, we noticed that partial improvement from SVH is achievable after SRS in the majority of patients. Our SRS candidates with SVH commonly underwent complex pain management before and after radiosurgery. Therefore, careful patient selection may be critical, and patients may require multiple treatment strategies for symptom control.
In monitoring the clinical response of patients, we see a positive response rate (80%), with durable responses usually at 1 year. These rates and timelines are consistent with those in the existing radiotherapy literature. 14, 19, 23 Miszczyk and Tukiendorf reported complete pain relief in 64% of patients at 1.5 years compared with 36% at 1 month. 18 This adds evidence to a hypothesis suggesting that SVH relief following SRS is more often a delayed outcome, unlike that seen in the prior SRS case report. 18, 25, 27 Regarding who may benefit most from SRS, our 2 patients who underwent initial decompression experienced the best pain control, and patients receiving adjuvant SRS were likely to improve. More evidence, however, is necessary to validate these positive correlations, as the radiotherapy literature has not found prior surgery to be predictive of favorable outcomes. 4, 14, 25 In the meantime, the use of conformal radiation therapy offers a conservative means of treatment while avoiding the risk of watershed infarct in the midthoracic spine or retropulsion of a posterior lesion embolization or vertebroplasty. 4, 11 It is also very encouraging that an appreciable radiographic response can be achieved. Within our cohort, those who presented with reductions in lesion size were also noted to improve clinically. Favorable outcomes exhibited on follow-up images obtained after radiotherapy and SRS for the treatment of such vascular malformations have been correlated with clinical improvement, particularly in the intracranial lesion literature. 9, [14] [15] [16] 21, 23, 25 However, the significance and likelihood of radiographic changes in the spine are still disputed. 14, 22 Predicting which lesions are most amenable to radiosurgical shrinkage should continue to be of ongoing interest for such vascular spinal lesions, as their extramedullary proximity to the spinal cord will be a major determinant of optimal SRS dosing when radiotherapy cannot achieve sufficient conformity.
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With regard to treatment planning for SVH, the SRS experience is still largely guided by the radiotherapy literature, and our series shows that current hypofractionated strategies remain consistently safe, without subsequent myelopathic injury or worsening of symptoms. 27 Sohn et al. experienced success with administering 32 Gy in 4 fractions for a 2.4-cm 3 lesion. 25 Our evidence demonstrates that SRS planning is feasible for much larger lesions and can achieve pain relief with fewer fractions. From the conventional fractionation literature, a higher dose, with a lower boundary of 35 Gy, increased the likelihood of pain control. 14, 18, 19 All patients from this series were safely administered an nBED greater than this recommended dose, adding continued evidence for this practice. For the 2 patients who exhibited regression in tumor size, both were treated with only 1 fraction, but with unrelated planning regimens, perhaps achieving a volumetric collapse given their large baseline sizes.
There exist significant limitations to our study. Namely, the small sample size precludes definitive conclusions regarding the efficacy of SRS. However, enough evidence exists to justify further investigation into larger controlled studies. Additional reporting of cases that build on our cohort will enable stratification of patients by their baseline symptom severities, comorbidities, and adjunct treatments to predict outcomes. The incorporation of postoperative and preoperative comprehensive pain assessments may also be valuable supplementary tools for trending the improvement of patients' complex symptoms following SRS.
Conclusions
Our clinical summaries suggest that some SVH patients present with complex comorbidities that potentially confound or reduce the benefit of any treatment response, radiosurgery or otherwise. It may be that a higher or complete response to primary SRS can be achieved in select patients who have clear, anatomically associated etiologies with susceptible tissue, thereby reducing multiple surgical procedures in nonemergent scenarios. Thus far, we have shown that SRS can be safely used as an adjunct in a multimodality approach to SVH and it can achieve appreciable success in large lesions. 
